# A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

> clinical trial · VERIFIED · 2026-06-16

Status: RECRUITING · Sponsor: AstraZeneca · Condition: HER2-positive Gastric Cancer

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06764875

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.